Published in Pharmacol Ther on November 01, 2006
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 1.05
Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol (2012) 1.00
Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods (2010) 0.99
Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein. Acta Crystallogr D Biol Crystallogr (2015) 0.96
Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med (2013) 0.94
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
Interindividual differences in phytochemical metabolism and disposition. Semin Cancer Biol (2007) 0.92
Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer (2010) 0.90
ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients. Front Genet (2012) 0.89
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression. Antimicrob Agents Chemother (2013) 0.89
Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol (2012) 0.87
Insights into Chemoresistance of Prostate Cancer. Int J Biol Sci (2015) 0.86
Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia. Arch Med Sci (2012) 0.86
Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. J Bioenerg Biomembr (2013) 0.85
Predictive computational models of substrate binding by a nucleoside transporter. J Biol Chem (2009) 0.85
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int (2008) 0.84
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med (2012) 0.83
Neuropsychiatric manifestations associated with azithromycin in two brothers. Eur J Clin Pharmacol (2010) 0.82
Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther (2008) 0.82
NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One (2011) 0.81
ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One (2014) 0.81
Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Sci Rep (2014) 0.81
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy. Cancer Res Treat (2014) 0.81
Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). Pharmacogenet Genomics (2011) 0.80
Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol (2007) 0.80
CIAPIN1 gene silencing enhances chemosensitivity in a drug-resistant animal model in vivo. Braz J Med Biol Res (2014) 0.78
Genetic and molecular changes in ovarian cancer. Cancer Biol Med (2016) 0.78
Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers. Eur J Clin Pharmacol (2012) 0.76
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget (2016) 0.76
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Sci Rep (2017) 0.75
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. Cancer Res Treat (2014) 0.75
Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res (2015) 0.75
In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.75
eUnaG: a new ligand-inducible fluorescent reporter to detect drug transporter activity in live cells. Sci Rep (2017) 0.75
Opioids Resistance in Chronic Pain Management. Curr Neuropharmacol (2017) 0.75
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmgenomics Pers Med (2016) 0.75
Quantitative Evaluation of Drug Resistance Profile of Cells Expressing Wild-Type or Genetic Polymorphic Variants of the Human ABC Transporter ABCC4. Int J Mol Sci (2017) 0.75
ABCB1 genetic variants in leukemias: current insights into treatment outcomes. Pharmgenomics Pers Med (2017) 0.75
Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae. Sci Rep (2017) 0.75
Noncoding RNA in drug resistant sarcoma. Oncotarget (2017) 0.75
ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. Oncotarget (2017) 0.75
Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1. Oncol Lett (2017) 0.75